Evidence map›Paper›PMID 30284080›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019

A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.

Kei Hosoda, Mizutomo Azuma, Chikatoshi Katada, Hiromitsu Moriya, Hiroaki Mieno, Kenji Ishido, Akira Ema, Hideki Ushiku, Takuya Wada, Marie Washio and 6 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Enhanced recovery versus conventional care in gastric cancer surgery: a meta-analysis of randomized and non-randomized controlled trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Pooled it
  2. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  3. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Therapeutic strategy for scirrhous type gastric cancer.Japanese journal of clinical oncology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer.World journal of gastrointestinal oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Kei HosodaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan. k.hosoda@kitasato-u.ac.jp.ORCID 0000-0002-9787-2889
Mizutomo AzumaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Chikatoshi KatadaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Hiromitsu MoriyaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Hiroaki MienoDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Kenji IshidoDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Akira EmaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Hideki UshikuDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Takuya WadaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Marie WashioDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Akinori WatanabeDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Katsuhiko HiguchiDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Satoshi TanabeDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Wasaburo KoizumiDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Masahiko WatanabeDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Keishi YamashitaDepartment of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis of patients with gastric cancer with bulky node metastasis, linitis plastica (type 4), or large ulcero-invasive-type tumors (type 3) remains poor. We conducted a phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 (DCS) for establishing a new treatment modality that improves prognosis.

methodsPatients received up to four 28-day cycles of DCS therapy (docetaxel at 40 mg/m

resultsBetween 2010 and 2017, 40 patients were enrolled. The R0 resection rate was 90%. The most common grade 3 or 4 adverse events during DCS therapy were leukocytopenia (27.5%), neutropenia (55.0%), and hyponatremia (22.5%). The most common grade 3 or 4 surgical morbidity was pancreatic fistula (12.5%); mortality was 0%. The pathological response rate was 57.5% with a grade 3 histological response rate of 8%.

conclusionsNeoadjuvant chemotherapy with DCS was feasible and showed a sufficient R0 resection rate. A future study with a sufficient follow-up period should confirm survival outcomes.

Indexed as

Neoadjuvant TherapyAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCisplatinDocetaxelDrug CombinationsFemaleFollow-Up StudiesGastrectomyHumansLymphatic MetastasisMaleMiddle AgedCisplatinDocetaxelDrug CombinationsOxonic AcidS 1 (combination)TegafurAdjuvant chemotherapyGastrectomyLinitis plasticaLymphatic metastasisStomach neoplasm

Identifiers

PMID30284080
OpenAlexW2894764110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.